PerkinElmer
check quantity

ProSense 750 FAST Fluorescent Imaging Agent

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

You successfully added item(s) to your cart

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV11171
689.00 USD
more
Buy Now

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Detail Information

ProSense® 750 FAST is part of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection. 

ProSense 750 FAST is a protease-activatable, pan-cathepsin fluorescent in vivo imaging agent that is activated by key disease associated proteases such as Cathepsin B, L, S, K, V and D. ProSense 750 FAST is not cleaved by trypsin or plasmin. 

Cathepsins are produced by inflammatory and tumor cells. ProSense 750 FAST is optically silent in its un-activated state and becomes highly fluorescent following protease-mediated activation. ProSense 750 FAST has a half-life in plasma of 30 minutes. ProSense 750 FAST may be used to study disease onset and progression in animal models of oncology, inflammation and atherosclerosis.

Specifications

Fluorescent Agent Type Activatable
Optical Imaging Classification Fluorescence Imaging
Product Brand Name ProSense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Unit Size 1 Vial (10 doses)
Wave Length 750 nm
Resources, Events & More
  • All

Application Note

In Vivo Imaging of Atherosclerosis Disease Using FMT

Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).

PDF 1 MB
Noninvasive In Vivo Quantitation of Asthma Severity Using FMT

Asthma is an inflammatory disease process characterized by reversible airway obstruction and airway hyperresponsiveness. This disease process is driven by activated T lymphocytes and eosinophils that are recruited to the lung upon inhalation of triggering allergens. These cells release inflammatory mediators, activate mast cells and epithelial cells and stimulate mucus secretion, ultimately leading to airway obstruction. The incidence and severity of asthma is increasing worldwide, elevating the need for clinically relevant in vivo animal models that can be used to improve the understanding of asthma biology and the development of effective therapeutics. Here we illustrate the use of PerkinElmer’s FMT® 2500LX Quantitative Pre-clinical Imaging System in combination with ProSense® 680 Fluorescent Pre-clinical Imaging Agent, a near-infrared, protease-activatable agent, for the noninvasive in vivo imaging and quantitation of pulmonary inflammation.

PDF 488 KB

Poster

Non-Invasive Quantitative Tomography of Disease Progression and Therapeutic Response

We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation with BAL assessment of eosinophilia, provide a powerful toolkit for quantifying the therapeutic efficacy of dexamethasone treatment. Utilizing new and existing imaging agents, FMT imaging in asthma research provides useful, non-invasive tools for understanding pulmonary inflammation and for developing new therapeutics in vivo.

PDF 581 KB

Technical Note

ProSense 750 FAST (Protocol)

ProSense 750 FAST activatable fluorescent imaging agent

PDF 258 KB
ProSense® 750 FAST (Data Sheet)

ProSense® 750 FAST is part of a family of activatable fluorescent imaging agents comprising a novel architecture termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection.

PDF 164 KB